Patent ID: 8580496

Claim:
A method to determine a signature of PIK3CA for treatment of early stage breast cancer in a patient, the method comprising: measuring an expression level of genes from a biopsy of a breast cancer tumour from the patient by contacting mRNA sequences from the cells of the said biopsy with a gene set of at least 3 capture nucleotide sequences that specifically hybridizes to RNA encoded by ARHGDIB, GALNT2 and PFN2 of a breast cell; determining the PIK3CA signature for said tumour, wherein under-expression of ARHGDIB and GALNT2 and/or overexpression of PFN2 corresponds to a wild-type PIK3CA signature; and administering to a patient comprising a breast cancer tumour having a wild-type PIK3CA signature a PI3-kinase inhibitor or a PI3-kinase pathway inhibitor.